Wei-Ying Jen

CONFLICT OF INTEREST STATEMENT Hagop Kantarjian reports honoraria and/or grant support from Amgen, Pfizer, and Takeda. Elias Jabbour reports consulting fees from Adaptive Biotechnologies Corporation, Autolus Ltd, Kite Pharma, and Novartis; and grant and/or contract funding from AbbVie, Amgen, Bristol-Myers Squibb, Pfizer, and Takeda Pharmaceuticals.

Abstract Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment differs. AA diagnosis relies on excluding IBMFS; however, genetic testing is not always available, may delay care or be inconclusive. We developed the Predictive Aplastic Score System (PASS), a clinical tool using readily available data to distinguish AA from IBMFS in adults. The training cohort included 212 adults (162 AA, 50 IBMFS).

To the Editor, Intensive induction and consolidation chemotherapy has long been the standard of care for fit patients with newly diagnosed acute myeloid leukemia (AML) [1-3]. Modifications to the traditional cytarabine-anthracycline backbone, including incorporation of purine analogs and high-dose cytarabine in consolidation, have been utilized to improve remission depth and long-term outcomes [4-6].